bioAffinity's Lung Cancer Test Achieves Over 100% Sales Growth in 2026
bioAffinity Technologies reported sales of its CyPath Lung diagnostic test more than doubled in the first three quarters of 2026 compared to the same period in 2025. The surge reflects growing adoption of the noninvasive test among clinicians for assessing lung cancer risk in high-risk populations. The strong performance demonstrates increasing market confidence in the company's early detection technology.
bioAffinity Technologies has achieved significant commercial momentum with its CyPath Lung diagnostic platform during 2026. The test represents a noninvasive approach to lung cancer risk assessment, addressing a clinical need among patient populations considered at elevated risk for the disease. This category of diagnostic tools plays an important role in the broader medical device landscape focused on early disease detection.
The doubling of sales over the nine-month period suggests that healthcare providers are increasingly incorporating the CyPath test into their clinical workflows. This adoption pattern indicates growing clinician confidence in the test's ability to help stratify patient risk and inform treatment decisions.
Widespread adoption of noninvasive lung cancer screening tools could potentially expand access to early detection across broader patient populations. Healthcare systems may benefit from diagnostic tests that could help identify high-risk individuals more efficiently. If adoption continues, such tools might influence clinical practice patterns around preventive medicine, though their ultimate impact would depend on factors including insurance coverage, regulatory approval pathways, and validation in diverse patient populations.